In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis

Antimicrob Agents Chemother. 1996 Oct;40(10):2428-30. doi: 10.1128/AAC.40.10.2428.

Abstract

Two oxazolidinones (U100592 and U100766), trovafloxacin, and a streptogramin combination (dalfopristin-quinupristin) were highly active in vitro against Staphylococcus aureus and Staphylococcus epidermidis, including methicillin-resistant strains. Trovafloxacin was more active than ciprofloxacin. Time-kill synergy studies demonstrated indifference for the oxazolidinones combined with vancomycin and rifampin against methicillin-resistant staphylococci. Spontaneous resistance was observed with all agents.

Publication types

  • Comparative Study

MeSH terms

  • Acetamides / pharmacology*
  • Anti-Bacterial Agents / pharmacology*
  • Drug Resistance, Microbial
  • Drug Synergism
  • Fluoroquinolones*
  • Humans
  • Linezolid
  • Microbial Sensitivity Tests
  • Naphthyridines / pharmacology*
  • Oxazoles / pharmacology*
  • Oxazolidinones*
  • Staphylococcal Infections / microbiology
  • Staphylococcus aureus / drug effects*
  • Staphylococcus epidermidis / drug effects*
  • Time Factors
  • Virginiamycin / pharmacology*

Substances

  • Acetamides
  • Anti-Bacterial Agents
  • Fluoroquinolones
  • Naphthyridines
  • Oxazoles
  • Oxazolidinones
  • Virginiamycin
  • quinupristin-dalfopristin
  • trovafloxacin
  • eperezolid
  • Linezolid